Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug? Hosted by Laycee KluinNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.8421 of 5 stars$874.12+0.1%0.69%74.65NVONovo Nordisk A/S4.6154 of 5 stars$88.07+5.2%0.82%26.77 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeatElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored7 Defensive Stocks to Shield Your Portfolio from Inflation Inflation is an unavoidable consequence of a market-based economy. In the best case, inflation is fueled by ...MarketBeatAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored20 "Past Their Prime" Stocks to Dump From Your PortfolioDid you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ...MarketBeatCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored10 Cheap Stocks Under $10 to Buy Now The stock market has largely recovered from its 2022 and 2023 slowdown and continues to hit new all time highs...MarketBeat Listen to MarketBeat Other Platforms 7 Inflation-Proof Stocks to Protect Your PortfolioInflation is sticking around—is your portfolio ready? In this video, we break down 7 stocks that could help shield your investments from inflation’s impact.Recent Videos Featured Articles and OffersNebius Group: NVIDIA’s Investment Sparks All-Time Highs February 19, 2025View Nebius Group: NVIDIA’s Investment Sparks All-Time Highs $5,000 DOGE check?From Altimetry(Ad)View $5,000 DOGE check?DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI StocksFebruary 18, 2025View DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks3 Stocks Poised to Thrive as NVIDIA Dominates the AI BoomFebruary 21, 2025View 3 Stocks Poised to Thrive as NVIDIA Dominates the AI BoomAnalysts See Buying Opportunity in NVIDIA Before EarningsFebruary 18, 2025View Analysts See Buying Opportunity in NVIDIA Before EarningsUrgent update to my gold outlookFrom Golden Portfolio(Ad)View Urgent update to my gold outlook Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Hosted by Laycee KluinNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.8421 of 5 stars$874.12+0.1%0.69%74.65NVONovo Nordisk A/S4.6154 of 5 stars$88.07+5.2%0.82%26.77 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeatElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored7 Defensive Stocks to Shield Your Portfolio from Inflation Inflation is an unavoidable consequence of a market-based economy. In the best case, inflation is fueled by ...MarketBeatAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored20 "Past Their Prime" Stocks to Dump From Your PortfolioDid you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ...MarketBeatCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored10 Cheap Stocks Under $10 to Buy Now The stock market has largely recovered from its 2022 and 2023 slowdown and continues to hit new all time highs...MarketBeat
